# ECOG-ACRIN Biospecimen Bank to Support NCTN

> **NIH NIH U24** · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · 2020 · $2,515,975

## Abstract

Project Summary
ECOG-ACRIN (EA) represents the merger of ECOG and ACRIN to form a cooperative group focused
on practice-changing clinical and translational research across the cancer care continuum from cancer
prevention and early detection, through the management of advanced disease and its impact. This application
is to support the infrastructure and banking operations for the EA Central Biorepository and Pathology
Facility (EA CBPF), a highly collaborative, productive and impactful biorepository resulting from the
consolidation of five NCI National Clinical Trials Network (NCTN) Biospecimen Banks, including one currently
finalizing transition. The consolidation of biorepository activities into EA CBPF has significantly impacted
operations by centralizing and continuing the standard and innovative biorepository activities and enhancing
capabilities to develop novel predictive biomarkers and therapeutic approaches in cancer. EA CBPF will
continue being assisted by the EA Biostatistics and Data Management Center (BDMC), Operations Offices,
other NCTN units, NCI-sponsored programs and investigators, and the NCI. The goal of EA CBPF is to ensure
the collection, storage, and distribution of well-annotated human biospecimens, procured from cancer patients
participating in the NIH/NCI and NCTN NCI-funded clinical treatment trials. EA CBPF's Aim 1 is to collect,
process, store, catalog, and distribute malignant and non-malignant tissues, cells, blood, and other fluid
specimens and their derivatives (e.g., tissue-derived and cell free DNA and RNA, proteins, exosomes and
circulating tumor cells) from patients enrolled in EA clinical trials following the NCI's “Best Practices for
Biospecimen Resources” and to link the specimens to relevant clinical, pathologic, immunological and
molecular data within the NCTN program; Aim 2 is to develop and utilize both routine and innovative
biospecimen resources that will aid in the successful completion of NCTN-supported clinical trials based on
integral biomarkers and of related correlative studies to promote the development of novel biomarker-driven
personalized cancer therapeutic strategies; Aim 3 is to develop capabilities for performing classic and
molecular methodologies on tissue, cell, blood, and other body fluid–based specimens from EA clinical trial
patients, including planned future consolidation of specimen-based functions, and provide expert
interpretation of the findings in close collaboration with the investigators leading the related NCTN- supported
clinical trials; and Aim 4 is to assist investigators outside and within the NIH/NCI NCTN and NCORP to
access biospecimens for research by participating actively, and leading efforts in high priority programs such
as the NCTN Navigator services and the Center for Immune Monitoring of Cancer (CIMAC), as well as
contributing actively to the biorepository harmonization activities of the NCI Group Banking Committee (GBC)
and NIH/NCI-supported specimen banking o...

## Key facts

- **NIH application ID:** 10071562
- **Project number:** 2U24CA196172-06
- **Recipient organization:** ECOG-ACRIN MEDICAL RESEARCH FOUNDATION
- **Principal Investigator:** STANLEY R. HAMILTON
- **Activity code:** U24 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $2,515,975
- **Award type:** 2
- **Project period:** 2015-04-29 → 2026-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10071562

## Citation

> US National Institutes of Health, RePORTER application 10071562, ECOG-ACRIN Biospecimen Bank to Support NCTN (2U24CA196172-06). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10071562. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*